Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Sclerosis | 116 | 2023 | 3079 | 9.580 |
Why?
|
Multiple Sclerosis, Relapsing-Remitting | 33 | 2023 | 518 | 4.140 |
Why?
|
Multiple Sclerosis, Chronic Progressive | 15 | 2023 | 236 | 2.270 |
Why?
|
Quality of Life | 25 | 2023 | 12804 | 1.470 |
Why?
|
Disability Evaluation | 28 | 2020 | 1827 | 1.440 |
Why?
|
Immunologic Factors | 8 | 2021 | 1580 | 1.310 |
Why?
|
Atrophy | 30 | 2023 | 1583 | 1.250 |
Why?
|
Disease Progression | 36 | 2022 | 13284 | 1.140 |
Why?
|
Magnetic Resonance Imaging | 74 | 2023 | 35421 | 1.110 |
Why?
|
Neurofilament Proteins | 8 | 2023 | 318 | 0.980 |
Why?
|
Brain | 47 | 2023 | 26385 | 0.960 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 3 | 2017 | 134 | 0.940 |
Why?
|
Severity of Illness Index | 32 | 2020 | 15540 | 0.920 |
Why?
|
Fatigue | 11 | 2021 | 1531 | 0.900 |
Why?
|
Spinal Cord | 11 | 2020 | 1809 | 0.820 |
Why?
|
Amyotrophic Lateral Sclerosis | 4 | 2018 | 1414 | 0.800 |
Why?
|
Models, Statistical | 9 | 2015 | 5102 | 0.780 |
Why?
|
Markov Chains | 5 | 2017 | 969 | 0.770 |
Why?
|
Interferon-beta | 4 | 2022 | 323 | 0.720 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2022 | 841 | 0.700 |
Why?
|
Cognitive Reserve | 2 | 2016 | 76 | 0.650 |
Why?
|
Demyelinating Diseases | 4 | 2016 | 354 | 0.630 |
Why?
|
MicroRNAs | 8 | 2023 | 3752 | 0.620 |
Why?
|
Mental Health | 7 | 2023 | 3019 | 0.580 |
Why?
|
JC Virus | 2 | 2014 | 85 | 0.580 |
Why?
|
Image Interpretation, Computer-Assisted | 9 | 2019 | 3327 | 0.570 |
Why?
|
Immunosuppressive Agents | 12 | 2021 | 4149 | 0.550 |
Why?
|
Longitudinal Studies | 35 | 2022 | 13989 | 0.550 |
Why?
|
Adult | 119 | 2023 | 214055 | 0.540 |
Why?
|
Computers | 1 | 2018 | 612 | 0.540 |
Why?
|
Humans | 206 | 2024 | 744343 | 0.530 |
Why?
|
Bayes Theorem | 3 | 2015 | 2309 | 0.520 |
Why?
|
Acute Coronary Syndrome | 9 | 2020 | 2337 | 0.520 |
Why?
|
Female | 147 | 2023 | 380194 | 0.510 |
Why?
|
Middle Aged | 111 | 2023 | 213383 | 0.500 |
Why?
|
Male | 140 | 2023 | 350118 | 0.480 |
Why?
|
Health Behavior | 8 | 2021 | 2636 | 0.480 |
Why?
|
Cognition Disorders | 6 | 2020 | 4043 | 0.470 |
Why?
|
Nerve Fibers, Myelinated | 6 | 2012 | 957 | 0.470 |
Why?
|
Anxiety | 5 | 2020 | 4297 | 0.460 |
Why?
|
Social Stigma | 1 | 2020 | 701 | 0.460 |
Why?
|
Depression | 11 | 2020 | 7766 | 0.450 |
Why?
|
Monocytes | 3 | 2019 | 2596 | 0.430 |
Why?
|
Models, Genetic | 3 | 2008 | 3494 | 0.430 |
Why?
|
Drug Resistance, Viral | 2 | 2008 | 820 | 0.420 |
Why?
|
Models, Psychological | 1 | 2016 | 811 | 0.420 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2010 | 323 | 0.400 |
Why?
|
Social Support | 3 | 2020 | 2118 | 0.400 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2023 | 9959 | 0.400 |
Why?
|
Research Design | 5 | 2017 | 5987 | 0.390 |
Why?
|
Optic Neuritis | 3 | 2021 | 166 | 0.380 |
Why?
|
Lymphocytes | 1 | 2019 | 2617 | 0.380 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2010 | 629 | 0.370 |
Why?
|
Gadolinium | 4 | 2020 | 952 | 0.370 |
Why?
|
Terminology as Topic | 2 | 2016 | 1547 | 0.350 |
Why?
|
HIV | 2 | 2008 | 1604 | 0.350 |
Why?
|
Glial Fibrillary Acidic Protein | 4 | 2023 | 528 | 0.350 |
Why?
|
Suicidal Ideation | 2 | 2016 | 1248 | 0.350 |
Why?
|
Efficiency | 1 | 2012 | 462 | 0.340 |
Why?
|
Receptors, Interleukin-6 | 2 | 2020 | 224 | 0.340 |
Why?
|
Drug Substitution | 2 | 2017 | 281 | 0.340 |
Why?
|
HLA-B Antigens | 1 | 2010 | 353 | 0.330 |
Why?
|
Parkinson Disease | 5 | 2023 | 2775 | 0.310 |
Why?
|
Models, Neurological | 1 | 2016 | 1774 | 0.310 |
Why?
|
Imaging, Three-Dimensional | 6 | 2018 | 4042 | 0.310 |
Why?
|
Self Report | 3 | 2015 | 3558 | 0.300 |
Why?
|
Organ Size | 6 | 2017 | 2252 | 0.300 |
Why?
|
Exercise | 8 | 2022 | 5615 | 0.290 |
Why?
|
Algorithms | 8 | 2021 | 13881 | 0.290 |
Why?
|
Disabled Persons | 3 | 2014 | 1212 | 0.290 |
Why?
|
Sample Size | 4 | 2017 | 845 | 0.290 |
Why?
|
Neutrophils | 1 | 2019 | 3719 | 0.280 |
Why?
|
Patient Satisfaction | 2 | 2021 | 3396 | 0.270 |
Why?
|
Recurrence | 11 | 2024 | 8340 | 0.270 |
Why?
|
Adjuvants, Immunologic | 4 | 2022 | 1000 | 0.270 |
Why?
|
Health Promotion | 7 | 2023 | 2205 | 0.250 |
Why?
|
Feasibility Studies | 12 | 2023 | 5078 | 0.240 |
Why?
|
Probiotics | 2 | 2018 | 351 | 0.240 |
Why?
|
Models, Theoretical | 2 | 2015 | 3589 | 0.240 |
Why?
|
Encephalomyelitis, Acute Disseminated | 2 | 2015 | 66 | 0.230 |
Why?
|
Young Adult | 36 | 2022 | 56430 | 0.230 |
Why?
|
Disease | 1 | 2009 | 680 | 0.230 |
Why?
|
Carrageenan | 1 | 2022 | 67 | 0.220 |
Why?
|
Dyspepsia | 1 | 2023 | 115 | 0.210 |
Why?
|
Age of Onset | 7 | 2022 | 3271 | 0.210 |
Why?
|
Autoantibodies | 2 | 2024 | 2035 | 0.200 |
Why?
|
Ferrous Compounds | 1 | 2001 | 42 | 0.200 |
Why?
|
Fatty Acid-Binding Proteins | 2 | 2021 | 300 | 0.190 |
Why?
|
Affect | 2 | 2019 | 1476 | 0.190 |
Why?
|
Upstream Stimulatory Factors | 1 | 2020 | 20 | 0.190 |
Why?
|
Spouse Abuse | 1 | 2022 | 178 | 0.190 |
Why?
|
Cognition | 10 | 2023 | 6770 | 0.190 |
Why?
|
Leptin | 3 | 2021 | 1599 | 0.190 |
Why?
|
Time Factors | 17 | 2020 | 40075 | 0.190 |
Why?
|
Integrative Medicine | 1 | 2022 | 87 | 0.190 |
Why?
|
DNA, Viral | 1 | 2007 | 2225 | 0.180 |
Why?
|
Platelet Transfusion | 1 | 2023 | 314 | 0.180 |
Why?
|
Blast Injuries | 1 | 2023 | 302 | 0.180 |
Why?
|
Phylogeny | 1 | 2007 | 2803 | 0.170 |
Why?
|
Encephalomyelitis, Autoimmune, Experimental | 2 | 2022 | 835 | 0.170 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2024 | 652 | 0.170 |
Why?
|
Cohort Studies | 20 | 2023 | 40561 | 0.170 |
Why?
|
Computer Simulation | 5 | 2012 | 6196 | 0.170 |
Why?
|
Adipokines | 1 | 2021 | 319 | 0.170 |
Why?
|
Probability | 3 | 2023 | 2505 | 0.170 |
Why?
|
Speech Perception | 1 | 2023 | 489 | 0.170 |
Why?
|
Speech | 1 | 2023 | 540 | 0.170 |
Why?
|
Adiponectin | 3 | 2021 | 1100 | 0.160 |
Why?
|
Finite Element Analysis | 1 | 2001 | 431 | 0.160 |
Why?
|
Intermediate Filaments | 3 | 2023 | 175 | 0.160 |
Why?
|
Sex Characteristics | 3 | 2015 | 2585 | 0.160 |
Why?
|
Retrospective Studies | 31 | 2024 | 77449 | 0.160 |
Why?
|
Interferons | 1 | 2022 | 706 | 0.160 |
Why?
|
Pattern Recognition, Automated | 3 | 2015 | 1005 | 0.160 |
Why?
|
Superior Sagittal Sinus | 1 | 2017 | 17 | 0.160 |
Why?
|
Evolution, Molecular | 1 | 2007 | 1940 | 0.160 |
Why?
|
Meninges | 1 | 2019 | 190 | 0.160 |
Why?
|
Treatment Outcome | 18 | 2022 | 63114 | 0.160 |
Why?
|
Contrast Media | 2 | 2014 | 5300 | 0.160 |
Why?
|
Antibodies, Viral | 4 | 2022 | 3176 | 0.150 |
Why?
|
Bifidobacterium | 1 | 2018 | 100 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2023 | 11725 | 0.150 |
Why?
|
Th17 Cells | 2 | 2022 | 766 | 0.150 |
Why?
|
Military Personnel | 2 | 2023 | 1133 | 0.150 |
Why?
|
Subtraction Technique | 2 | 2011 | 525 | 0.150 |
Why?
|
Psychotherapy | 2 | 2019 | 1643 | 0.150 |
Why?
|
Pilot Projects | 9 | 2023 | 8324 | 0.150 |
Why?
|
Teaching Rounds | 1 | 2021 | 253 | 0.150 |
Why?
|
Risk | 4 | 2019 | 9687 | 0.150 |
Why?
|
Prospective Studies | 16 | 2023 | 53288 | 0.150 |
Why?
|
Wine | 1 | 2017 | 165 | 0.140 |
Why?
|
Blood Transfusion | 1 | 2023 | 1301 | 0.140 |
Why?
|
Logistic Models | 7 | 2020 | 13408 | 0.140 |
Why?
|
Optic Nerve | 1 | 2020 | 554 | 0.140 |
Why?
|
Vision Tests | 1 | 2017 | 167 | 0.140 |
Why?
|
Radiometry | 2 | 2003 | 800 | 0.140 |
Why?
|
Peptides | 5 | 2013 | 4409 | 0.140 |
Why?
|
Cerebral Cortex | 3 | 2018 | 5708 | 0.140 |
Why?
|
Folic Acid | 1 | 2023 | 1300 | 0.140 |
Why?
|
Postmenopause | 2 | 2015 | 2461 | 0.140 |
Why?
|
Neuropsychological Tests | 7 | 2020 | 6993 | 0.130 |
Why?
|
Sickness Impact Profile | 2 | 2015 | 302 | 0.130 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2022 | 570 | 0.130 |
Why?
|
Psychotherapy, Group | 1 | 2019 | 406 | 0.130 |
Why?
|
Lower Extremity | 1 | 2023 | 1158 | 0.130 |
Why?
|
Smoking | 3 | 2023 | 8987 | 0.130 |
Why?
|
Computers, Handheld | 1 | 2017 | 208 | 0.130 |
Why?
|
HLA Antigens | 2 | 2010 | 1381 | 0.130 |
Why?
|
Aged | 29 | 2023 | 163280 | 0.130 |
Why?
|
Predictive Value of Tests | 9 | 2015 | 15076 | 0.120 |
Why?
|
Early Diagnosis | 1 | 2020 | 1184 | 0.120 |
Why?
|
Personal Satisfaction | 1 | 2019 | 643 | 0.120 |
Why?
|
Injections | 1 | 2017 | 840 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2023 | 5442 | 0.120 |
Why?
|
Propylene Glycols | 1 | 2014 | 92 | 0.120 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9274 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 4 | 2013 | 17446 | 0.120 |
Why?
|
Sensitivity and Specificity | 11 | 2017 | 14722 | 0.120 |
Why?
|
Vaccines | 1 | 2022 | 822 | 0.110 |
Why?
|
Adolescent | 23 | 2023 | 85781 | 0.110 |
Why?
|
Abortion, Spontaneous | 1 | 2018 | 544 | 0.110 |
Why?
|
Heart Diseases | 3 | 2016 | 2788 | 0.110 |
Why?
|
Uveal Neoplasms | 1 | 2016 | 310 | 0.110 |
Why?
|
Medical Informatics | 1 | 2020 | 745 | 0.110 |
Why?
|
Statistics, Nonparametric | 4 | 2017 | 2886 | 0.110 |
Why?
|
Reproducibility of Results | 9 | 2017 | 19905 | 0.110 |
Why?
|
Body Mass Index | 6 | 2021 | 12720 | 0.110 |
Why?
|
Prognosis | 10 | 2020 | 29063 | 0.110 |
Why?
|
Neurology | 1 | 2021 | 763 | 0.110 |
Why?
|
Visual Acuity | 3 | 2021 | 2530 | 0.110 |
Why?
|
Calibration | 1 | 2015 | 816 | 0.110 |
Why?
|
Aging | 4 | 2021 | 8664 | 0.110 |
Why?
|
Databases, Factual | 4 | 2019 | 7729 | 0.110 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 977 | 0.110 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 264 | 0.110 |
Why?
|
Behavior Therapy | 1 | 2018 | 865 | 0.110 |
Why?
|
Cross-Sectional Studies | 12 | 2021 | 25043 | 0.110 |
Why?
|
Models, Biological | 1 | 2009 | 9583 | 0.100 |
Why?
|
Serologic Tests | 1 | 2014 | 374 | 0.100 |
Why?
|
HLA-DR Antigens | 2 | 2010 | 645 | 0.100 |
Why?
|
Sphingosine | 1 | 2014 | 307 | 0.100 |
Why?
|
Image Enhancement | 5 | 2020 | 2921 | 0.100 |
Why?
|
Osteopontin | 1 | 2013 | 296 | 0.100 |
Why?
|
Postpartum Period | 1 | 2018 | 1086 | 0.100 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1889 | 0.100 |
Why?
|
Inflammation | 3 | 2019 | 10638 | 0.100 |
Why?
|
Food Hypersensitivity | 1 | 2018 | 622 | 0.100 |
Why?
|
Neuromyelitis Optica | 1 | 2015 | 252 | 0.100 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2133 | 0.100 |
Why?
|
Data Interpretation, Statistical | 3 | 2013 | 2716 | 0.100 |
Why?
|
Cervical Vertebrae | 2 | 2015 | 975 | 0.100 |
Why?
|
Absenteeism | 1 | 2012 | 250 | 0.100 |
Why?
|
Boston | 4 | 2020 | 9313 | 0.100 |
Why?
|
Incidence | 7 | 2023 | 20947 | 0.100 |
Why?
|
Follow-Up Studies | 12 | 2023 | 39050 | 0.100 |
Why?
|
Receptor, Adenosine A1 | 1 | 2010 | 44 | 0.100 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2703 | 0.100 |
Why?
|
Random Allocation | 1 | 2015 | 2429 | 0.100 |
Why?
|
Regression Analysis | 3 | 2011 | 6459 | 0.090 |
Why?
|
Panic Disorder | 1 | 2014 | 616 | 0.090 |
Why?
|
Inpatients | 2 | 2013 | 2518 | 0.090 |
Why?
|
Patient Compliance | 2 | 2019 | 2684 | 0.090 |
Why?
|
Models, Economic | 2 | 2016 | 713 | 0.090 |
Why?
|
Phenotype | 5 | 2020 | 16365 | 0.090 |
Why?
|
HLA-C Antigens | 1 | 2010 | 147 | 0.090 |
Why?
|
Plasma | 2 | 2020 | 575 | 0.090 |
Why?
|
Receptor, Adenosine A2A | 1 | 2010 | 124 | 0.090 |
Why?
|
Heart Failure | 3 | 2021 | 10900 | 0.090 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2010 | 163 | 0.090 |
Why?
|
HLA-A Antigens | 1 | 2010 | 231 | 0.090 |
Why?
|
Vision Disorders | 1 | 2017 | 1058 | 0.090 |
Why?
|
Probability Theory | 1 | 2009 | 10 | 0.090 |
Why?
|
Levodopa | 1 | 2010 | 219 | 0.090 |
Why?
|
Health Care Costs | 2 | 2016 | 3209 | 0.090 |
Why?
|
Likelihood Functions | 2 | 2016 | 1005 | 0.090 |
Why?
|
Cytokines | 3 | 2020 | 7322 | 0.090 |
Why?
|
Administration, Oral | 1 | 2017 | 3913 | 0.090 |
Why?
|
Albuterol | 1 | 2010 | 208 | 0.090 |
Why?
|
Cell Migration Inhibition | 1 | 2009 | 96 | 0.090 |
Why?
|
Leukoencephalopathies | 1 | 2012 | 238 | 0.090 |
Why?
|
Antiparkinson Agents | 1 | 2010 | 184 | 0.090 |
Why?
|
Epidemiologic Research Design | 1 | 2013 | 367 | 0.090 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2009 | 141 | 0.090 |
Why?
|
HIV-1 | 1 | 2007 | 6939 | 0.090 |
Why?
|
Personality | 1 | 2013 | 552 | 0.090 |
Why?
|
Resilience, Psychological | 1 | 2016 | 676 | 0.080 |
Why?
|
Reference Values | 3 | 2011 | 4982 | 0.080 |
Why?
|
Pyrroles | 1 | 2015 | 1146 | 0.080 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2291 | 0.080 |
Why?
|
Thalamus | 2 | 2018 | 1023 | 0.080 |
Why?
|
Employment | 1 | 2015 | 1132 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2019 | 3508 | 0.080 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2022 | 2988 | 0.080 |
Why?
|
Attitude | 1 | 2013 | 776 | 0.080 |
Why?
|
Walking | 3 | 2013 | 1180 | 0.080 |
Why?
|
Normal Distribution | 1 | 2009 | 280 | 0.080 |
Why?
|
Insulin Resistance | 2 | 2020 | 3864 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1061 | 0.080 |
Why?
|
Feeding Behavior | 1 | 2020 | 3188 | 0.080 |
Why?
|
Androgens | 1 | 2015 | 1281 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2013 | 969 | 0.080 |
Why?
|
Suicide, Attempted | 1 | 2016 | 1221 | 0.080 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 310 | 0.080 |
Why?
|
Patient Care | 1 | 2013 | 640 | 0.080 |
Why?
|
Poisson Distribution | 1 | 2009 | 513 | 0.080 |
Why?
|
Sex Distribution | 2 | 2011 | 2297 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2010 | 601 | 0.070 |
Why?
|
Brain Infarction | 1 | 2009 | 299 | 0.070 |
Why?
|
HIV Reverse Transcriptase | 1 | 2008 | 213 | 0.070 |
Why?
|
Interferon Type I | 1 | 2011 | 542 | 0.070 |
Why?
|
Medulla Oblongata | 1 | 2008 | 243 | 0.070 |
Why?
|
Risk Factors | 9 | 2023 | 72290 | 0.070 |
Why?
|
Chi-Square Distribution | 2 | 2010 | 3508 | 0.070 |
Why?
|
Gene Frequency | 2 | 2010 | 3588 | 0.070 |
Why?
|
Genes, Viral | 1 | 2008 | 718 | 0.070 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2006 | 52 | 0.070 |
Why?
|
Testosterone | 2 | 2014 | 2420 | 0.070 |
Why?
|
Child | 13 | 2024 | 77709 | 0.070 |
Why?
|
Pregnancy Complications | 1 | 2020 | 2861 | 0.070 |
Why?
|
Clinical Trials as Topic | 3 | 2014 | 7913 | 0.070 |
Why?
|
Prothrombin Time | 1 | 2006 | 119 | 0.070 |
Why?
|
Basal Ganglia | 1 | 2009 | 546 | 0.070 |
Why?
|
Age Distribution | 2 | 2009 | 2902 | 0.070 |
Why?
|
Cerebrospinal Fluid | 1 | 2009 | 534 | 0.070 |
Why?
|
New England | 1 | 2009 | 1022 | 0.070 |
Why?
|
Age Factors | 7 | 2020 | 18370 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2014 | 6538 | 0.070 |
Why?
|
Artifacts | 1 | 2014 | 1904 | 0.070 |
Why?
|
Attitude to Health | 1 | 2015 | 2052 | 0.070 |
Why?
|
Comorbidity | 1 | 2020 | 10388 | 0.070 |
Why?
|
Biometry | 1 | 2009 | 558 | 0.070 |
Why?
|
Recovery of Function | 2 | 2014 | 2925 | 0.070 |
Why?
|
Blood Component Transfusion | 1 | 2006 | 143 | 0.070 |
Why?
|
Splenectomy | 1 | 2007 | 395 | 0.070 |
Why?
|
Linear Models | 4 | 2017 | 5952 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 3022 | 0.070 |
Why?
|
Prevalence | 4 | 2022 | 15226 | 0.070 |
Why?
|
Telephone | 2 | 2020 | 617 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2013 | 1411 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 3712 | 0.060 |
Why?
|
Emotions | 1 | 2017 | 2661 | 0.060 |
Why?
|
Alzheimer Disease | 2 | 2023 | 8037 | 0.060 |
Why?
|
Corpus Callosum | 1 | 2009 | 737 | 0.060 |
Why?
|
Diffusion Tensor Imaging | 2 | 2012 | 2305 | 0.060 |
Why?
|
Platelet Count | 2 | 2023 | 781 | 0.060 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2008 | 615 | 0.060 |
Why?
|
Seasons | 1 | 2010 | 1493 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3143 | 0.060 |
Why?
|
Patient Care Team | 1 | 2016 | 2531 | 0.060 |
Why?
|
Alcohol Drinking | 1 | 2017 | 3966 | 0.060 |
Why?
|
Genome, Viral | 1 | 2008 | 667 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2018 | 8949 | 0.060 |
Why?
|
HIV Protease Inhibitors | 1 | 2006 | 430 | 0.060 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12354 | 0.060 |
Why?
|
Iron | 2 | 2009 | 1774 | 0.060 |
Why?
|
Gait | 1 | 2009 | 793 | 0.060 |
Why?
|
HIV Infections | 2 | 2008 | 16718 | 0.060 |
Why?
|
Survival Analysis | 2 | 2015 | 10252 | 0.060 |
Why?
|
Mental Disorders | 2 | 2013 | 6600 | 0.060 |
Why?
|
Blood Coagulation Disorders | 1 | 2006 | 337 | 0.060 |
Why?
|
Memory | 1 | 2013 | 2174 | 0.060 |
Why?
|
Explosions | 1 | 2023 | 109 | 0.060 |
Why?
|
Nasal Sprays | 1 | 2022 | 18 | 0.060 |
Why?
|
Depressive Disorder | 2 | 2013 | 3748 | 0.050 |
Why?
|
Kidney Neoplasms | 1 | 2019 | 4262 | 0.050 |
Why?
|
Software | 2 | 2015 | 4443 | 0.050 |
Why?
|
Pancreatectomy | 1 | 2007 | 804 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 2016 | 5391 | 0.050 |
Why?
|
Genotype | 3 | 2013 | 12951 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2024 | 343 | 0.050 |
Why?
|
Vitamin B 6 | 1 | 2023 | 237 | 0.050 |
Why?
|
Administration, Intranasal | 1 | 2023 | 446 | 0.050 |
Why?
|
Antigens, CD20 | 1 | 2022 | 199 | 0.050 |
Why?
|
rho-Associated Kinases | 1 | 2023 | 279 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5751 | 0.050 |
Why?
|
Immunoconjugates | 1 | 2008 | 901 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2011 | 6622 | 0.050 |
Why?
|
Arrhythmias, Cardiac | 1 | 2011 | 2268 | 0.050 |
Why?
|
Spleen | 1 | 2007 | 2362 | 0.050 |
Why?
|
Internet | 1 | 2013 | 3064 | 0.050 |
Why?
|
Receptors, CCR6 | 1 | 2020 | 81 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2022 | 12026 | 0.050 |
Why?
|
Sucrose | 1 | 2001 | 164 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 141 | 0.050 |
Why?
|
Solutions | 1 | 2001 | 426 | 0.050 |
Why?
|
Spinal Cord Injuries | 1 | 2008 | 931 | 0.050 |
Why?
|
Sodium Chloride | 1 | 2022 | 625 | 0.050 |
Why?
|
British Columbia | 1 | 2020 | 244 | 0.050 |
Why?
|
Analysis of Variance | 3 | 2014 | 6365 | 0.040 |
Why?
|
Vitamin B 12 | 1 | 2023 | 527 | 0.040 |
Why?
|
Vaccination | 2 | 2022 | 3278 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 132 | 0.040 |
Why?
|
Pharynx | 1 | 2022 | 413 | 0.040 |
Why?
|
Gels | 1 | 2001 | 427 | 0.040 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 15165 | 0.040 |
Why?
|
Receptors, CXCR3 | 1 | 2020 | 237 | 0.040 |
Why?
|
Coronary Artery Disease | 2 | 2019 | 6487 | 0.040 |
Why?
|
Chelating Agents | 1 | 2001 | 380 | 0.040 |
Why?
|
REM Sleep Behavior Disorder | 1 | 2020 | 105 | 0.040 |
Why?
|
Patient Readmission | 1 | 2013 | 3114 | 0.040 |
Why?
|
Abortion, Therapeutic | 1 | 2018 | 35 | 0.040 |
Why?
|
Radiography | 1 | 2010 | 7023 | 0.040 |
Why?
|
Auditory Perception | 1 | 2023 | 569 | 0.040 |
Why?
|
Prednisone | 1 | 2024 | 1574 | 0.040 |
Why?
|
Diffusion | 1 | 2001 | 833 | 0.040 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2023 | 644 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11524 | 0.040 |
Why?
|
Adaptation, Psychological | 1 | 2009 | 2576 | 0.040 |
Why?
|
Antidepressive Agents | 1 | 2011 | 2838 | 0.040 |
Why?
|
T-Lymphocytes | 2 | 2023 | 10180 | 0.040 |
Why?
|
Carnitine | 1 | 2020 | 246 | 0.040 |
Why?
|
GTP-Binding Proteins | 1 | 2023 | 970 | 0.040 |
Why?
|
DNA Mutational Analysis | 1 | 2007 | 4186 | 0.040 |
Why?
|
Sex Factors | 3 | 2019 | 10397 | 0.040 |
Why?
|
Ownership | 1 | 2020 | 332 | 0.040 |
Why?
|
Puerperal Disorders | 1 | 2020 | 275 | 0.040 |
Why?
|
Case-Control Studies | 4 | 2020 | 21746 | 0.040 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2009 | 2737 | 0.040 |
Why?
|
Melanoma | 1 | 2016 | 5510 | 0.040 |
Why?
|
Leukopenia | 1 | 2017 | 212 | 0.040 |
Why?
|
Cytomegalovirus | 1 | 2022 | 732 | 0.040 |
Why?
|
Lactobacillus | 1 | 2018 | 189 | 0.040 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12261 | 0.040 |
Why?
|
Aged, 80 and over | 4 | 2023 | 57776 | 0.040 |
Why?
|
Th1 Cells | 1 | 2022 | 1057 | 0.040 |
Why?
|
Biological Assay | 1 | 2020 | 652 | 0.040 |
Why?
|
Neurons | 2 | 2022 | 9338 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2009 | 4560 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2022 | 1041 | 0.040 |
Why?
|
Eating | 1 | 2023 | 1536 | 0.040 |
Why?
|
Mutation | 2 | 2013 | 29786 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3870 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2003 | 1184 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2020 | 4420 | 0.030 |
Why?
|
Obesity | 2 | 2021 | 12745 | 0.030 |
Why?
|
Constipation | 1 | 2020 | 546 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2007 | 4803 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2016 | 4933 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2017 | 793 | 0.030 |
Why?
|
Lymphopenia | 1 | 2017 | 285 | 0.030 |
Why?
|
Endothelin-1 | 1 | 2017 | 314 | 0.030 |
Why?
|
Demyelinating Autoimmune Diseases, CNS | 1 | 2015 | 32 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2016 | 552 | 0.030 |
Why?
|
Genetic Variation | 2 | 2009 | 6544 | 0.030 |
Why?
|
Signal Transduction | 3 | 2020 | 23403 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2019 | 599 | 0.030 |
Why?
|
Pregnancy Trimester, First | 1 | 2018 | 853 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 954 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2618 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2003 | 1624 | 0.030 |
Why?
|
Hemorrhage | 1 | 2006 | 3461 | 0.030 |
Why?
|
Aquaporin 4 | 1 | 2015 | 153 | 0.030 |
Why?
|
Autoimmunity | 1 | 2022 | 1349 | 0.030 |
Why?
|
tau Proteins | 1 | 2023 | 1868 | 0.030 |
Why?
|
Phorbol Esters | 1 | 2013 | 111 | 0.030 |
Why?
|
Online Systems | 1 | 2014 | 184 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2017 | 1588 | 0.030 |
Why?
|
Neurotic Disorders | 1 | 2013 | 79 | 0.030 |
Why?
|
United States | 5 | 2023 | 69872 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2020 | 4386 | 0.030 |
Why?
|
Pregnancy | 3 | 2020 | 29144 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2017 | 1155 | 0.030 |
Why?
|
Steroids | 1 | 2018 | 930 | 0.030 |
Why?
|
Mice | 4 | 2023 | 81183 | 0.030 |
Why?
|
Survivors | 1 | 2023 | 2291 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2001 | 2480 | 0.030 |
Why?
|
Blood Platelets | 1 | 2023 | 2508 | 0.030 |
Why?
|
Chemokine CXCL10 | 1 | 2013 | 304 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2008 | 4256 | 0.030 |
Why?
|
Gene Expression Regulation | 3 | 2018 | 12072 | 0.030 |
Why?
|
Nurses | 1 | 2021 | 2461 | 0.020 |
Why?
|
Health Surveys | 2 | 2013 | 4037 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3505 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 1836 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 2682 | 0.020 |
Why?
|
Metabolomics | 1 | 2020 | 1484 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2017 | 899 | 0.020 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2010 | 45 | 0.020 |
Why?
|
Interferon-gamma | 2 | 2010 | 3206 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1339 | 0.020 |
Why?
|
SEER Program | 1 | 2016 | 1508 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 2023 | 3587 | 0.020 |
Why?
|
Critical Care | 1 | 2023 | 2647 | 0.020 |
Why?
|
Oxidopamine | 1 | 2010 | 169 | 0.020 |
Why?
|
Glutamine | 1 | 2013 | 578 | 0.020 |
Why?
|
Adrenergic Agents | 1 | 2010 | 70 | 0.020 |
Why?
|
Cost Savings | 1 | 2016 | 926 | 0.020 |
Why?
|
Enkephalins | 1 | 2010 | 154 | 0.020 |
Why?
|
Dynorphins | 1 | 2010 | 84 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2023 | 3297 | 0.020 |
Why?
|
Personality Inventory | 1 | 2013 | 1030 | 0.020 |
Why?
|
Animals | 5 | 2023 | 168757 | 0.020 |
Why?
|
Verbal Behavior | 1 | 2011 | 339 | 0.020 |
Why?
|
Vitamin D | 2 | 2014 | 3223 | 0.020 |
Why?
|
Arginine | 1 | 2013 | 944 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 950 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 2987 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.020 |
Why?
|
Health Status | 2 | 2016 | 4034 | 0.020 |
Why?
|
Health Resources | 1 | 2016 | 911 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1683 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2022 | 21827 | 0.020 |
Why?
|
Odds Ratio | 2 | 2013 | 9849 | 0.020 |
Why?
|
Interferon Regulatory Factors | 1 | 2010 | 270 | 0.020 |
Why?
|
Adrenergic beta-Agonists | 1 | 2010 | 346 | 0.020 |
Why?
|
Anisotropy | 1 | 2012 | 1265 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2017 | 13033 | 0.020 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2017 | 1573 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1504 | 0.020 |
Why?
|
Health Personnel | 1 | 2022 | 3218 | 0.020 |
Why?
|
Interleukin-13 | 1 | 2010 | 389 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4445 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2715 | 0.020 |
Why?
|
Brain Mapping | 1 | 2023 | 6669 | 0.020 |
Why?
|
Demography | 1 | 2013 | 1656 | 0.020 |
Why?
|
Movement Disorders | 1 | 2011 | 445 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2023 | 6234 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7799 | 0.020 |
Why?
|
Child, Preschool | 3 | 2016 | 41006 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1590 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2017 | 6038 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1956 | 0.020 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2009 | 675 | 0.020 |
Why?
|
Protein Precursors | 1 | 2010 | 1154 | 0.020 |
Why?
|
Estrogens | 1 | 2013 | 1566 | 0.020 |
Why?
|
Syndrome | 1 | 2012 | 3251 | 0.020 |
Why?
|
Caffeine | 1 | 2010 | 699 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2023 | 7880 | 0.020 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9239 | 0.020 |
Why?
|
Survival Rate | 1 | 2019 | 12788 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7149 | 0.020 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2013 | 2015 | 0.020 |
Why?
|
Overweight | 1 | 2016 | 2371 | 0.020 |
Why?
|
Pancreatic Diseases | 1 | 2007 | 350 | 0.020 |
Why?
|
Memory, Short-Term | 1 | 2011 | 975 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2022 | 11483 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2009 | 1663 | 0.020 |
Why?
|
Drug Resistance | 1 | 2010 | 1609 | 0.020 |
Why?
|
Area Under Curve | 1 | 2009 | 1654 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2015 | 5974 | 0.020 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2003 | 5221 | 0.020 |
Why?
|
Cardiovascular Agents | 1 | 2011 | 850 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9438 | 0.020 |
Why?
|
Thoracic Vertebrae | 1 | 2009 | 608 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2017 | 5097 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2013 | 4204 | 0.020 |
Why?
|
Corpus Striatum | 1 | 2010 | 1221 | 0.010 |
Why?
|
Psychometrics | 1 | 2013 | 3002 | 0.010 |
Why?
|
Body Composition | 1 | 2013 | 2401 | 0.010 |
Why?
|
Coronary Angiography | 1 | 2015 | 4577 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6895 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2013 | 2050 | 0.010 |
Why?
|
Adiposity | 1 | 2013 | 1807 | 0.010 |
Why?
|
Immune System | 1 | 2008 | 805 | 0.010 |
Why?
|
Secondary Prevention | 1 | 2009 | 1530 | 0.010 |
Why?
|
Homeostasis | 1 | 2013 | 3340 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2009 | 1904 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2013 | 3279 | 0.010 |
Why?
|
Creatinine | 1 | 2006 | 1919 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6489 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6933 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7785 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12245 | 0.010 |
Why?
|
Insulin | 1 | 2013 | 6580 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2009 | 5524 | 0.010 |
Why?
|
Massachusetts | 1 | 2011 | 8663 | 0.010 |
Why?
|
Registries | 1 | 2013 | 8089 | 0.010 |
Why?
|
Telemedicine | 1 | 2014 | 2872 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2003 | 2879 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2016 | 7659 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10943 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2009 | 4479 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2010 | 14557 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 23338 | 0.010 |
Why?
|
Infant | 1 | 2016 | 35136 | 0.010 |
Why?
|
Hospitalization | 1 | 2013 | 10262 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 19229 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2010 | 18029 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2007 | 15295 | 0.000 |
Why?
|
Lung Neoplasms | 1 | 2003 | 13102 | 0.000 |
Why?
|